AzTrials
AzTrials

Urinary StonesNCT01100580

The Links Between Water and Salt Intake, Body Weight, Hypertension and Kidney Stones: a Difficult Puzzle

A study testing low salt diet and water therapy in people with Urinary Stones and Hypertension, run by University of Parma at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Nephrolithiasis is a disease that strikes roughly 10% of the Italian population and its incidence in industrialized countries is on the increase. The most common form of the disease (80%) is Idiopathic Calcium Nephrolithiasis (ICN) with calcium-oxalate (CaOx) and/or calcium-phosphate (CaP) stones. Read more about this study

Who is it for?
Ages 20 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Urinary Stones, Hypertension, Overweight
What is being tested?
low salt diet and water therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
350 participants
Where
1 siteItaly
Study dates
May 2010to May 2012
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

For the stone formers main inclusion criteria

  • age between 20 and 70 years
  • caucasian race
  • idiopathic calcium stone disease
  • normal renal function (creatininemia <1.2 mg/dl)

Main exclusion criteria

  • other major diseases
  • diseases affecting the mineral and electrolyte metabolism (diabetes, endocrine diseases, inflammatory diseases etc.)
  • treatments affecting the mineral and electrolytic metabolism (vitamin D, acetazolamide, anti-epilectic drugs, steroids etc).

Trial locations and contacts

1 site in 1 country.

Loris Borghi, Prof contact

+390521703375

loris.borghi@unipr.it

Italy1 site
  • University of Parma

    Parma, 43100

    Loris Borghi, Prof, +390521703375, loris.borghi@unipr.it

    Loris Borghi, Prof

Other trials in Italy

About this study

Nephrolithiasis is a disease that strikes roughly 10% of the Italian population and its incidence in industrialized countries is on the increase. The most common form of the disease (80%) is Idiopathic Calcium Nephrolithiasis (ICN) with calcium-oxalate (CaOx) and/or calcium-phosphate (CaP) stones. The etiopathogenesis involves both genetic and acquired factors, the interplay of which leads to urinary biochemical anomalies at the root of stone formation. The elements and urinary compounds involved are known as "urinary stone risk factors". The risk factors for CaOx stones consist of low urine volume, hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia and hypomagnesuria. In the case of CaP stones, the hyperphosphaturia and pH parameters are of particular importance; a pH>7 promotes the formation of stones prevalently composed of phosphates, while a pH of between 6 and 7, associated with a volume <1l/day, can raise CaP supersaturation to a dangerously high level and lead to the formation of mixed CaOx and CaP stones. For uric acid stones, the elements involved are hyperuricosuria and pH<5.5. In general, the most prevalent alteration in ICN is hypercalciuria (50%). Hypertension and obesity are also social diseases with important epidemiological similarities to nephrolithiasis. These affinities have led to the search for a common pathogenic moment. As far as hypertension is concerned, various studies have demonstrated high calciuria in hypertensives with a linear relationship between 24-h calciuria and arterial blood pressure. The incidence of stone disease is greater in hypertensives than in normotensives and, by the same token, the incidence of hypertension is greater in stone formers than in non stone formers, but it is not clear whether nephrolithiasis is a risk factor for hypertension or vice versa. Moreover, a linear relationship exists between calciuria and natriuria, where the calcium is the dependent variable, with a much steeper slope of the straight line in stone formers and hypertensives compared to controls. It has, in fact, been demonstrated that to reduce calcium, it is more efficacious to reduce sodium intake as opposed to calcium intake. Finally, BMI and body weight are independently associated with an increase in stone risk even though, due to a number of bias (limited weight categories, low number of obese persons in the study populations, no control group, no recording of food intake) the studies published failed to be conclusive. In the final analysis, stone disease, arterial hypertension and excess weight/obesity prove to be closely interconnected and it is possible to intervene with targeted diets aimed at reducing the risk of illness and death from these diseases. Among such dietary approaches, the reduction of sodium chloride in food, increased hydration and an increased intake of foods with an alkaline potential seem to play an important role.

For many years now, the investigators research unit has been involved in projects, partially financed by the Italian Ministry of University and Research (MIUR), geared towards studying the effects induced by dietary changes in patients with calcium stone disease. The aim of the present project is to analyse in depth the relationship between stone disease, hypertension, body weight and water and salt intake both in the general population of the area of Parma (where historically and by gastronomic tradition, the usual diet tends to have a high salt content) and in a selected population of stone formers and hypertensives not under treatment. A representative sample of the population of the area of Parma will be studied, divided on the basis of weight category, in order to assess water and salt intake and relationships with the presence of hypertension, and a sample of normal and hypertensive stone formers randomized to receive for one year either water therapy+low salt diet or water therapy alone.

Read the detailed description

Background and rationale

Nephrolithiasis is a disease that could be defined as social, due to its widespread distribution and its continually increasing incidence in industrialized countries with a high standard of living (1). In Italy, it strikes just under 10% of the population, leading to expenditure of approx. 200 million euro/year for hospital admissions alone (2). Idiopathic Calcium Nephrolithiasis (ICN) with the formation of calcium oxalate stones, sometimes mixed with calcium phosphate ones, is the most common form, having an incidence of roughly 80% (3,4). As regards distribution in the two sexes, a slightly higher incidence in males has been observed. The pathogenesis of ICN involves both genetic and acquired factors (5), the combining of which leads to urinary biochemical anomalies which lie at the root of stone formation. A high rate of calcium-oxalate and/or calcium-phosphate supersaturation leads to the formation of nests of crystals that can then grow and aggregate to form a stone. The elements and urine compounds involved in the process of crystallization, whether they be inhibitors or promoters, are known as urinary stone risk factors. For Ca-oxalate they are: low urine volume (<2 l/day), hypercalciuria (>250mg/day), hyperoxaluria (>40 mg/day), hyperuricosuria (>600 mg/day), hypocitraturia (<320 mg/day) and hypomagnesuria (<50 mg/day). For Ca-phosphate, in addition to the above-mentioned factors, hyperphosphaturia (>1000 mg/day) and urinary pH also acquire considerable importance: a pH>7 promotes the formation of stones prevalently composed of phosphates, while a pH of between 6 and 7 associated with a urine volume <1l/day, can dangerously raise Ca-phosphate supersaturation and lead to the formation of mixed Ca-oxalate and Ca-phosphate stones. Finally, for uric acid stone disease the elements involved are hyperuricosuria and pH < 5.5. Among the stone risk factors, the most common found in the urine of patients affected by ICN is hypercalciuria with an incidence of around 50%. With regard to age of onset, there are two peaks, one between 20 and 30 years of age and one between 50 and 60.

Hypertension and obesity are also widespread social diseases with important epidemiological similarities to nephrolithiasis. These affinities have, over the years, led investigators to seek interconnections between the three diseases in order to find a common pathogenic moment. As far as hypertension is concerned, various studies have demonstrated that urinary excretion of calcium is greater in hypertensives than in normotensives. A linear association between the excretion of 24-h calcium and arterial blood pressure has been demonstrated in numerous studies, including INTERSALT (6). In 1999, after following up 132 hypertensives and 135 controls for 5 years, our group published a paper which reported the onset of stone disease in the hypertensives in significantly higher percentages compared to the controls, with an RR of 5.5 (7). Moreover, a year earlier, Madore and Curhan published two studies (8,9) conducted on a large cohort of Americans in which they demonstrated that patients with a past history of nephrolithiasis without hypertension were more prone to become hypertensive during the follow-up than non stone formers. These results, further confirmed by many subsequent studies, did not however succeed in clarifying the doubt as to whether it is the hypercalciuria of hypertensives that predisposes them to the development of stone disease or whether it is the renal damage, albeit microscopic, caused by stone disease that triggers the development of hypertension. Scientific literature has, however, identified, for hypertensives, stone formers and controls alike, a linear relationship between the excretion of calcium and the excretion of sodium, where calcium is the dependent variable and where the slope of the straight line, i.e. the increase of calcium for each mmol of sodium, is much greater in both stone formers and hypertensives than in controls. Moreover, as far back as the '80s, it was demonstrated that a reduction in kitchen salt intake from 10 g to 4 g per day, has the capacity to reduce calciuria more than a reduction in calcium intake from 1000 mg to 500 mg (10,11).

In 2002, we confirmed this experimental data with a paper published in the New England Journal of Medicine in which we demonstrated in recurrent male hypercalciuric stone formers followed up for 5 years, that a normal calcium, low-salt, low-protein diet had the power to reduce both the calciuria and the stone recurrences much more significantly than a low-calcium diet (12). Obviously it was not possible to separate the effect of the restriction of sodium from the restriction of protein. Both diets were accompanied by the recommendation to drink water, the effectiveness of which had already been demonstrated in first-episode stone formers in a previous study randomized with a follow-up of 5 years conducted on 199 stone formers and 101 controls (13).

The central role of body weight in determining stone risk is clearly described in scientific literature. BMI, weight, abdominal circumference are independently associated with kidney stone risk (14). Nevertheless, the mechanisms underlying this relation are still unknown. Data exist in literature to suggest that body weight can affect the excretion of many promoters or inhibitors of crystalline aggregation. For example, some population studies in the United States have demonstrated how urine pH is inversely correlated to body weight and how urinary excretion of calcium, oxalate and uric acid increase as body weight increases (15,16). Notwithstanding these data, the effects of body weight on the excretion of many urinary stone risk factors remains partly unknown; this is due to the limited weight categories, the low number of obese people in the study populations, the absence of a control group with "non stone formers" and the failure to record food intake in the studies published. In addition to this, as regards urinary excretion, the evaluation of excess weight solely on the basis of BMI values and abdominal circumference may seem somewhat reductive. It would appear to be more useful to assess body composition, lean mass, fat tissue mass and mineral mass. In this way, by better stratifying obesity classes, it might become simpler to understand the intricate endocrine/metabolic changes that occur in obesity (hyperinsulinism, hyperestrogenism etc.) and establish better correlations with the urinary excretion of stone risk factors. In fact, some studies (16) have demonstrated a slight increase in the total incidence of stone disease in female obese patients compared to males, with a slightly higher mean age in the females and, in any case, ages being equal, with a lower number of recurrences in the females compared to the males. These phenomena are probably affected by the concentration of serum estrogens and by the transformation in the fatty tissue of the adrenal androgens into estrogens; nonetheless the effects of serum estrogens on the urinary excretion of calcium are unknown. Finally, some studies have demonstrated that body weight also affects the composition of the stones. In fact, it has been demonstrated how the incidence of uric acid stones is higher in overweight/obese patients than in normal weight patients; some studies have highlighted that patients with idiopathic uric acid nephrolithiasis have a higher BMI than hyperuricosuric patients who form calcium oxalate stones. The pathophysiological link should be sought in hyperinsulinism: in fact insulin resistance is associated with a decrease in the production of renal ammonia leading to a consequent decrease in urinary pH, characteristic of uric acid stone disease (17). This theory is indirectly corroborated by the aforementioned indirect relationship between BMI and 24-h urine pH and the finding that also age-related reduced urinary acidification capacity increases the risk of uric stone disease, irrespective of body weight. On the basis of the above, it is clear how the presence of excess weight/obesity, uric acid or mixed stone disease could raise suspicions of a Metabolic Syndrome: there are, however, no conclusive studies on this, and neither have the effects on stone risk and arterial blood pressure of water therapy and a low-salt diet in a population of overweight/obese stone formers been sufficiently studied.

In the final analysis, nephrolithiasis, arterial hypertension and excess weight/obesity prove to be closely interconnected and it is possible to develop targeted diets aimed at reducing the risk of illness and death from this disease. Among such dietary approaches, the reduction of sodium chloride in food, increased hydration and an increased intake of foods with an alkaline potential (18) seem to play an important role.

For many years now, our research unit has been involved in projects, partially financed by the Italian Ministry of University and Research (MIUR), geared towards studying the effects induced by dietary changes in patients with calcium stone disease. The aim of the present project is to deepen our knowledge on the relationship between stone disease, hypertension, body weight and water and salt intake both in the general population of the area of Parma, where historically and by gastronomic tradition the normal diet tends to have a high salt content, and in a selected population of stone formers and hypertensives.

Experimental design/description of methodologies

As already mentioned, the aim of this project is to attempt to clarify the relationship between idiopathic calcium stone disease, salt and water intake, hypertension and body weight.

The study will be divided into two sub-projects:

  1. Assessment of the salt and water intake in the general population of the area of Parma (duration 24 months)
  2. Assessment of the effects of a low salt + water therapy diet vs water therapy alone for one year in patients with idiopathic calcium stone disease, both male and female, normal- and hypertensive without treatment (duration 12 months)

At least 350 healthy controls, 100 hypertensive non stone formers without treatment, 150 normotensive stone formers and 100 hypertensive stone formers without treatment will be enrolled in the study. Both the controls and the stone formers will be subdivided according to a 4-class BMI scale. The classes will have the following characteristics: Class 1 BMI £ 18.9 (underweight condition); Class 2 BMI between 19 and 24.9 (normal weight condition); Class 3 BMI between 25 and 29.9 (excess weight condition); Class 4 BMI > 30 (obesity). The patients enrolled will have their medical history recorded after which they will be subjected to the measurement of anthropometric parameters and arterial blood pressure, and a stone risk mini-profile will be drawn up including volume, creatinine, sodium, potassium and calcium measured according to the methods published. As is well-known, 24-h urinary sodium is considered the "gold standard" for the assessment of food-related salt intake, creatinine is a sensitive marker of lean mass, potassium is an index of the body's alkaline potential and calcium has the important pathophysiological role described above.

The stone formers will be randomized to receive a low salt+water therapy diet or water therapy alone, for one year. The term "water therapy" refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer). For stone formers only, at the end of the 12 month period of therapy, anthropometric parameters and arterial blood pressure will be measured once more and the urinary mini-profile will be repeated.

Objectives

Sub-project 1) "Assessment of the salt and water intake in the general population of the area of Parma"

Primary objective To assess the consumption of kitchen salt (NaCl) and the water intake in the general population of the area of Parma after adjustment for the BMI, and to study any possible relationships with the presence of arterial hypertension.

Secondary objectives

  1. To study the urinary sodium-calcium relationship in the general normo- and hypertensive population without treatment.
  2. To confirm the described relationship between 24-h calciuria and arterial blood pressure.
  3. To identify any correlations between BMI and urinary solutes.
  4. To stratify the salt and water intake by age category.
  5. To assess the stone risk in the general normo- and hypertensive population without treatment.
  6. To define urinary sodium-potassium-volume relationships in the general normo- and hypertensive population without treatment.

Sub-project 2) "Assessment of the effects of a low salt + water therapy diet vs water therapy alone for one year in patients with idiopathic calcium stone disease, both male and female, normal- and hypertensive without treatment (duration 12 months)"

Primary objective To assess the effects of a low-salt diet + water therapy vs water therapy alone, maintained for one year, on calciuria, arterial blood pressure and body weight in normo- and hypertensive stone formers.

Secondary objectives

  1. To study the urinary sodium-calcium relationship in normo- and hypertensive stone formers without treatment and compare it with matched non stone formers.
  2. To study the relationship between 24-h calciuria and arterial blood pressure in stone formers and compare it with matched non stone formers.
  3. To identify any correlations between BMI and urinary solutes and evaluate the differences with matched non stone formers.
  4. To stratify the salt and water intake by age category and recurrence rate in recurrent stone formers.
  5. To assess the compliance with the low salt diet after one year.
  6. To define the urinary sodium-potassium-volume relationships in normo- and hypertensive stone formers without treatment and compare them with matched non stone formers.
Being tested
low salt diet, water therapy
Keywords
Low-salt diet, calciuria, blood pressure, nephrolithiasis, hypertension, BMI, urinary stone risk factors
Medical subject headings
Urinary Calculi, Hypertension, Overweight, Obesity, Nephrolithiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • low salt dietDietary supplement

    Daily salt intake less than 4 g/day

  • water therapyDietary supplement

    abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).

Study groups in NCT01100580
Study groupRoleWhat they receive
water therapyActive comparatorThe term "water therapy" refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
Receives: Dietary Supplement: water therapy
low salt diet + water therapyExperimentallow salt diet refers to a salt intake of 4 g/day
Receives: Dietary Supplement: low salt diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. normalization of urinary stone risk factors

    Measured: one year

Secondary outcomes (6)
  1. urinary sodium/calcium relationship

    Measured: one yaer

  2. blood pressure reduction

    Measured: one year

  3. relationship between 24h-calciuria and blood pressure

    Measured: one year

  4. stone rate reduction

    Measured: one year

  5. correlation BMI-urinary stone risk factors

    Measured: one year

  6. compliance

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Apr 2010 (estimated)
  2. Study startMay 2010
  3. Primary completionMay 2011 (estimated)
  4. Study completionMay 2012 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
350 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01100580
Sponsor's protocol ID
FORST-1028
Status last verified
Apr 2010
First submitted
29 Mar 2010
Last updated
9 Apr 2010
Results posted
No
Data monitoring committee
Yes

Publications

  • Goldfarb DS. Increasing prevalence of kidney stones in the United States. Kidney Int. 2003 May;63(5):1951-2. doi: 10.1046/j.1523-1755.2003.00942.x. No abstract available.

    PubMed 12675877
  • Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, Marmot M. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ. 1996 May 18;312(7041):1249-53. doi: 10.1136/bmj.312.7041.1249.

    PubMed 8634612
  • Goulding A, McParland BE. Fasting and 24-h urinary sodium/creatinine values in young and elderly women on low-salt and salt-supplemented regimens. J Cardiovasc Pharmacol. 1990;16 Suppl 7:S47-9.

    PubMed 1708023
  • Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002 Jan 10;346(2):77-84. doi: 10.1056/NEJMoa010369.

    PubMed 11784873
  • Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005 Jan 26;293(4):455-62. doi: 10.1001/jama.293.4.455.

    PubMed 15671430

Questions about this trial

What is this clinical trial studying?

A study testing low salt diet and water therapy in people with Urinary Stones and Hypertension, run by University of Parma at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Apr 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Loris Borghi, Prof (+390521703375, loris.borghi@unipr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

normalization of urinary stone risk factors (time frame: one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01100580, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in